E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Not applicable (including healthy volunteers). |
No procede (inclusión de voluntarios sanos). |
|
E.1.1.1 | Medical condition in easily understood language |
Not applicable (including healthy volunteers). |
No procede (inclusión de voluntarios sanos). |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Behaviours [F01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Main objective is to assess the proportionality of 3 pirlindole doses (50, 100 and 150 mg) administered orally in healthy volunteers. |
Como objetivo principal se plantea evaluar la proporcionalidad de 3 dosis de pirlindol (50, 100 y 150 mg) administradas por vía oral en voluntarios sanos. |
|
E.2.2 | Secondary objectives of the trial |
A secondary objective is to evaluate the safety of 3 pirlindole doses administered in healthy volunteers. |
Como objetivo secundario se evaluará la seguridad de las 3 dosis de pirlindol administradas en voluntarios sanos. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1- Subjects of either gender (male or female), with an age between 18 and 45 years. 2.- Body weight within the normal range (Quetelet index between 18 and 29, expressed as weight (kg) / height (m2). 3.- Medical history, physical examination by organs, both within normal limits. 4.- No evidence of significant disease (organic or psychiatric) based on the anamnesis taking, physical examination and complementary tests. 5.- Laboratory tests (complete blood count and chemistry) within the normal range, according to the normal reference values of the chemistry laboratory of the Hospital de la Santa Creu i Sant Pau. Variations may be admitted, in accordance with the CIM?s clinical criterion. 6.- Vital signs (systolic and diastolic blood pressure, heart rate and temperature) and ECG record within normal range. 7.- Participating female volunteers must use contraceptive measures other than oral contraceptives. 8.- To have granted consent to participating in the study, with a written informed consent signed by the volunteer prior to inclusion in the study. |
1- Sujetos de ambos sexos (masculino o femenino), con una edad entre 18 y 45 años. 2- peso corporal dentro del rango normal (indice Quetelet entre 18 y 29, expresado como peso (kg) / altura (m). 3- historia medica, examen físico por organos, ambos dentro limites normales. 4- Sin evidencia de enfermedades significativas (organica o psiquiatrica) basada en la anamnesis, examen físico y test complementarios. 5- examenes de laboratorio (contaje y quimica sanguinea) en rango normal de acuerdo con los valores del laboratorio del Hospital de la Santa Creu i Sant Pau. Se permitiran variacines de acuerdo con los criterios clínicos del CIM. 6- Signos vitales (presión sanguinea diastolica y sistolica, frecuancia cardiaca, temperatura) y ECG dentro del rango normal. 7- Participantes femeninas deben utilizar otras medidas anticonceptivas diferentes a los anticonceptivos orales. 8-Haber firmado el consentimiento informado antes de la inclusión en el estudio. |
|
E.4 | Principal exclusion criteria |
1.- History of allergy, idiosyncrasy or hypersensitivity to drugs. 2.- Heavy consumer of stimulating drinks (> 5 cups of coffee, tea, chocolate or cola drinks per day). 3.- Prior history of alcohol consumption or use or abuse of recreational drugs. 4.- Use of any medications within 2 weeks prior to taking the study treatment (except for the use of acetaminophen in short-term symptomatic treatments), including over-the-counter medications and medicinal plants. 5.- Positive serology for hepatitis B, C, or for the HIV virus. 6.- A history or clinical evidence of cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, haematological, neurological disease, or other chronic diseases. 7.- To have undergone surgery during the previous 6 months. 8.- Smokers. 9.- Pregnancy or breast-feeding. 10.- To have participated in another clinical trial during the three months prior to starting the current trial. 11.- To have donated blood in the 4 weeks prior to starting the study. |
1.- Historia de alergia, idiosincrasia o hipersensibilidad a las drogas. 2.- consumidores asiduos de bebidas estimulantes (> 5 tazas de café, té, chocolate o cola por día). 3.- historia previa de consumo de alcohol o uso o abuso de drogas recracionales. 4.- uso de cualquier medicación dentro de las 2 semanas anteriores a la toma de medicación del estudio. 5.- Serología positiva para hepatitis B, C, o para HIV. 6.- historia, o evidencia clínica de enfermedad cardiovascular, respiratoria, renal hepatica, endocrina, gastrointestinal, hematologica, neurologica, o otra enfermedad cronica. 7.- Haber recibido cirugía durante los 6 mese previos. 8.- Fumadores. 9.- Embarazadas o madres en periodo de lactancia. 10.- Haber participato en otro ensayo clínico durante los 3 mese previos al inicio de este ensayo. 11.- Haber donado sangre en las 4 semanas previas al inicio del estudio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary pharmacokinetic parameters will be obtained after a non-compartmental approach: AUC0 t , AUC0? and Cmax of pirlindole, after oral administration of 3 doses evaluated (50, 100 and 150 mg). These parameters will be used to assess the linearity of the 3 administered doses from the power model described by Hummel et al. (Hummel, McKendrick et al. 2009). |
El parámetro farmacocinético primario se obtendra luego de una aproxcimación No-Compartimental: AUC0t, AUC0? y Cmax de pirlindol, luego de administración oral de 3 dosis (50, 100 y 150 mg). Estos parametros serán usados para comprobar linearidad de las 3 dosis administradas |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Blood samples will be taken (10 ml) at the following times: baseline (pre-dose), + 10 '+ 20' + 30' + 45' + 1h, + 1h15 ', + 1h30', 1h45 ',+ 2h, + 3h, 5h +, + 6h, +8 h, +12 h and +24 h post-dose (total 15 points extraction). |
Las muestras sanguineas serán tomadas (10 ml) en los tiempos siguientes: pre-dosis, + 10 '+ 20' + 30' + 45' + 1h, + 1h15 ', + 1h30', 1h45 ',+ 2h, + 3h, 5h +, + 6h, +8 h, +12 h and +24 h post-dosis (total de 15 extracciones) |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints are: tmax, t1/2, CL/F and V/F of pirlindole after administration of the 3 doses evaluated. It will also assess the safety of 3 doses of pirlindole by adverse effects, vital signs (SBP / DBP and HR) and laboratory parameters. |
Endpoint secundarios son. tmax, t1/2, CL/F y V/F de pirlindol luego de la administración de 3 dosis evaluadas. También se evaluará la seguridad de las 3 dosis de pirlindol por aparicióne de efectos adversos, signos vitales, y parametros de laboratorio. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Blood samples will be taken (10 ml) at the following times: baseline (pre-dose), + 10 '+ 20' + 30' + 45' + 1h, + 1h15 ', + 1h30', 1h45 ',+ 2h, + 3h, 5h +, + 6h, +8 h, +12 h and +24 h post-dose (total 15 points extraction). |
muestras sanguineas serán tomadas (10 ml) en los tiempos siguientes: pre-dosis, + 10 '+ 20' + 30' + 45' + 1h, + 1h15 ', + 1h30', 1h45 ',+ 2h, + 3h, 5h +, + 6h, +8 h, +12 h and +24 h post-dosis (total de 15 extracciones) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The clinical trial can be interrupted at the discretion of the principal investigator or Tecnimede, S.A. in any of these cases: - Occurrence of an unknown adverse event, or known adverse events but with unexpected seriousness, duration or incidence. - Insufficient number of volunteers included in the study. - Cancellation of drug development. |
el ensayo clínico será interrumpido a discreción del investigador principal o Tecnimede, S.A. en cualquiera de estos casos: -Evento adverso desconocido, o conocido pero inesperadamente serio, en duración o incidencia. -Número insuficiente de voluntarios incluidos en el estudio. -Cancelación del envío del medicamento. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | |